Adipokine Visfatin Induces Redox Molecular Trafficking and Dysfunction in Coronary Endothelial Cells

Department of Pharmacology and Toxicology Virginia Commonwealth University Spur Program 2009 Jessica B. Cardwell

Background



Background

- Visfatin, a recently discovered adipocytokine, was found at high levels in obesity, type 2 diabetes and chronic kidney disease patients.
- Our studies show that visfatin can induce the impairment of the Endothelium Dependent Vasodilation.

Hypothesis



Question 1

Whether Visfatin can influence vessel function?

Effect of Visfatin on EDVD



Question 2

What is the mechanism by which Visfatin induced impairment of endothelium dependent vasodilation?

Visfatin Induced Lipid Raft Clustering



Question 3

Whether NADPH Oxidase is involved in the lipid raft aggregation?

Co-localization of NADPH Oxidase Subunits with Lipid Raft



Conclusion

- Visfatin can induce the impairment of EDVD.
- Visfatin can stimulate lipid raft aggregation which can be blocked by lipid raft blockers MCD and Filipin.
- ASM is involved in the Visfatin induced lipid raft formation which can be blocked by Amitryptiline.
- Visfatin can activate NADPH Oxidase and together result in colocalization with lipid raft.

Acknowledgements

- Dr. Pin-Lan Li
- Mark
- Summer Students
- Li Lab

